$NUVB

Sauvage Philippe sold $286K of NUVB

Sauvage Philippe (Chief Financial Officer) sold 47,668 shares of Nuvation Bio Inc. (NUVB) at $6.01 ($0.29M total) on 2026-06-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sauvage Philippe
Published Jun 24, 2026, 11:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 11:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NUVB
Neutral
medium confidence
Mentioned
$NUVB
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVBNeutralLow
01

Why it matters

The disclosure updates the insider activity record (shares sold, price, post-transaction holdings) but does not provide new operating or financial guidance.

02

Market read

Traders may monitor for follow-on insider activity, but this single 10b5-1 sale is usually not a standalone trading catalyst.

03

What to watch

The filing does not disclose reasons for the sale; traders should avoid inferring directionality without corroborating operational or guidance news.

Relevance 3/10Novelty 4/10Timing: Filed 2026-06-24 after-hours; reflects sale executed 2026-06-23

Background

The article is an SEC Form 4 insider transaction for Nuvation Bio, reported by the CFO.

Company-level read

Ticker impact

$NUVBNeutralMedium confidence
Context

Nuvation Bio CFO Sauvage Philippe sold 47,668 shares in an open-market transaction at $6.0076/share under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be small and short-lived unless paired with other new company news.

Evidence & confidence

Form 4 provides a concrete datapoint (size, price, 10b5-1), but insider sales—especially under pre-arranged plans—are typically not a standalone catalyst.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • NUVATION BIO INC.

    Company whose CFO reported an open-market sale of shares via a 10b5-1 plan.

  • Sauvage Philippe

    Chief Financial Officer who sold 47,668 shares at $6.0076/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NUVBMed

JPMorgan sees 100% upside in overlooked cancer drug stock

JPMorgan initiated coverage of Nuvation Bio (NUVB) with an Overweight rating and a $13 price target, implying 100% upside. The bank cited strong sales of IBTROZI, a lung cancer drug launched in 2026, and potential from safusidenib, an experimental brain tumor drug. Nuvation reported Q2 2026 revenue of $31.7M, beating estimates, but still operating at a loss. The stock has fallen 18% YTD but gained 8% in the past five days.

$NUVBHighAI 8/10

Why is Nuvation Bio stock rallying today?

Nuvation Bio (NUVB) stock rose 2.8% to $7.02 after the FDA granted Fast Track Designation to safusidenib, its therapy for IDH1-mutant glioma, citing Phase 2 study data. Cantor Fitzgerald initiated coverage with an Overweight rating and $12 price target, projecting peak sales of $965M for IBTROZI and $1.9B for safusidenib. The broader market also showed gains.

$NUVBHigh

Nuvation Bio stock rises after Cantor starts at Overweight

Nuvation Bio (NUVB) shares rose 2.7% after Cantor Fitzgerald initiated coverage with an Overweight rating and $12 price target. Analyst Li Watsek highlighted two therapies, Ibtrozi and safusidenib, with peak sales estimates of $965M and $1.9B respectively, suggesting significant upside. Cantor also noted potential strategic interest in the company.

$NUVBMedAI 8/10

Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript

Nuvation Bio (NUVB) reported Q2 2026 revenue of $31.7M, including $23.2M IBTROZI product revenue and $8.5M collaboration and license revenue. IBTROZI net product revenue grew 25% QoQ to $23.2M, with 160 new patient starts. Net loss was $62.8M. Cash and marketable securities were $661M. The company raised $279.1M via convertible notes and expects a potential $30M Eisai EU milestone in 1H 2027.